Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Vilamakitug · XB-2001

Monoclonal antibody · Antagonist of interleukin-1 alpha (IL1A) · developed by XBiotech

Phase 2 Most advanced trial
XBIT Developer
2 Registered trials

What is Vilamakitug?

Vilamakitug is a human IgG4 monoclonal antibody that binds and inhibits interleukin-1 alpha (IL1a), an inflammatory cytokine. It is studied in pancreatic cancer and axial spondyloarthritis, targeting IL1a-mediated tumorigenesis, angiogenesis, and cachexia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
XB-2001, Natrunix
Drug type
Monoclonal antibody
Targets
interleukin-1 alpha (IL1A)
Mechanism
Antagonist of interleukin-1 alpha (IL1A)
Pathways
angiogenesis, tumorigenesis, cachexia
Therapy area
Oncology
Developer
XBiotech, Inc. (XBIT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
3562YZ5W3H

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06526377 Phase 2 Axial Spondyloarthritis Not yet recruiting XBIT
NCT04825288 Phase 1/2 Pancreatic Cancer Completed XBIT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ankylosing SpondylitisAxial SpondyloarthritisNr-axSpAr-axSpAPancreatic Cancer

Other drugs acting on IL1A

Hutrukin Phase 1 Lutikizumab Phase 2 Natrunix Phase 2

More from XBiotech

514G3 Phase 1/2 Hutrukin Phase 1 Natrunix Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the XBIT page.

Follow XBIT, the company behind Vilamakitug

See XBIT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XBIT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.